| Emitents | Grindeks, AS (5299006DWR32NKWM1O86) |
| Veids | Finanšu pārskati |
| Valoda | EN |
| Statuss | Publicēts |
| Versija | |
| Datums | 2008-02-27 09:08:19 |
| Versijas komentārs | |
| Teksts |
Today, on 27 February, Joint Stock Company Grindeks has presented to Riga Stock Exchange non-audited consolidated financial report about the results of 2007. Non-audited financial results are evidence, that the Group of Grindeks worked successfully during last year– net profit, related to the shareholders of the holding company, in 2007 amounted to 7.2 million lats, which is by 8.8% more than in 2006. In 2007 turnover of the Group amounted to 51.5 million lats, which is by 9.3 million lats or 22% more than during the same period in 2006. Chairman of the Board of Grindeks Janis Romanovskis denoted, that the positive financial results, shown during 2007, confirm the development of the Company in accordance with its chosen strategic aims. „Significant investments are our utmost guarantor in the development - almost 9 million lats in 2007. The unique in the Baltic States Analytical and Scale-up Laboratory Completed is certified at international level, the production of disposable ready-made medications is continued, and the building of modern waste water purification equipment is started. The growth of Grindeks medications sales` volume in existent markets is uninterruptedly continuous; moreover, we started the registration of various medications in the perspective markets, such as China and Turkey”.
The significant profit increase was received as a result of sales volume growth by 22%, related to sales of ready-made medications. Sales volume of ready-made medications amounted to 47.7 million lats in 2007, which is by 8.7 million lats or 22% more than during 2006. Mostly, the largest volume of medications was delivered in the main export markets - in Russia and CIS countries, the total sum amounted to 41.7 million lats. It’s already traditionally, that during accounting period the most turnover – 73% of the total sales volume of the ready-made medications was formed by sales of original product Mildronate®,what exceeded the result of 2006 by 6.2 million lats or 22%. Positive measures of profit were also obtained as the result of increase in export of active pharmaceutical ingredients (API), the growth of export reached 3.8 million lats, which is by 0.7 million lats or 22% more than during 2006. The main export markets for API produced by Grindeks are Europe, Japan, the USA, Australia, Pakistan, India. In 2008 Grindeksintends to significantly improve product portfolio and offer four new generics. Development of new original products will be also continued. With the aim to develop productiveness and effectiveness of enterprise, in 2008 the Group will continue to work at the increase of its shareholders’ value, by increasing sales volumes in the existing and new attractive markets, as well as improving effectiveness of operations. Further information: Laila Klavina Head of the Communications Department JSC “Grindeks” Phones: +371 67083370, +371 29256012 e-mail: laila_klavina@grindeks.lv |
| Pielikumi |